Company / R&D Expense
Whitehawk Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$51.0M
FY2025
5-year range
$15.0M / $51.0M
FY2021-FY2025
Trend
+4.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 5 consecutive years, from $13M in FY2020 to $51M in FY2025.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +31.8%.
Improved from $33M to $51M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +37.4%
- 5-Year CAGR
- +31.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Whitehawk Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +31.8%, indicating consistent growth.
- In FY2025, r&d expense increased 4.3% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.0M | +4.3% |
| FY2024 | $48.9M | +49.8% |
| FY2023 | $32.7M | +66.0% |
| FY2022 | $19.7M | +31.1% |
| FY2021 | $15.0M | +17.0% |
| FY2020 | $12.8M | -28.2% |
| FY2019 | $17.9M | +47.0% |
| FY2018 | $12.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026